Evofem biosciences, inc. (EVFM)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Operating expenses:
Research and development

18,588

22,230

28,570

32,758

39,345

43,415

44,859

41,271

33,516

23,539

21,524

16,226

13,576

14,855

12,681

26,927

32,969

34,409

29,298

15,029

8,492

5,174

0

0

0

Selling and marketing

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

General and administrative

33,029

30,512

25,163

25,111

29,825

34,227

33,148

27,373

18,244

12,148

18,583

16,681

15,493

15,083

6,721

7,585

8,222

7,639

6,776

5,930

5,251

4,416

0

0

0

Total operating expenses

58,354

52,742

54,851

58,987

70,288

77,642

78,007

68,644

51,760

35,687

44,812

37,612

33,774

34,643

19,402

34,512

41,192

42,049

36,075

20,960

13,744

9,591

0

0

0

Loss from operations

-58,354

-52,742

-54,851

-58,987

-70,288

-77,642

-78,007

-68,644

-51,760

-35,687

-44,812

-37,612

-33,774

-34,643

-19,402

-34,512

-41,192

-42,049

-36,075

-20,960

-13,744

-9,591

0

0

0

Other income (expense):
Interest income

542

458

368

191

115

127

130

127

127

128

121

103

88

77

55

47

38

26

24

19

14

7

0

0

0

Other expense

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income (expense), net

-

-

236

-84

-

-145

-149

-158

-62

-46

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Loss on issuance of Series D redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

8,522

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Loss on issuance of warrants

-

-

0

0

-

47,920

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on issuance of Purchase Rights

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,214

996

1,127

1,133

1,057

901

642

374

0

0

0

Fair Value Adjustment of Warrants

3,315

7,755

7,755

7,755

4,440

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

860

0

0

0

Change in fair value of Purchase Rights

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of Series D 2X liquidation preference

-

-

0

0

-

-130

-1,494

-60,705

-60,955

-61,175

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Total other income (expense), net

-22,753

-27,287

-27,442

-27,939

-4,434

-48,068

-52,215

-117,178

-117,332

-69,615

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Loss before income tax

-81,107

-80,029

-82,293

-86,926

-74,722

-125,710

-130,222

-185,822

-169,092

-105,302

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Income tax expense

4

4

4

6

0

-

0

0

-

3

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net Income (Loss) Attributable to Parent

-81,111

-80,033

-82,297

-86,930

-74,724

-125,712

-130,224

-185,824

-169,092

-105,305

-141,432

-69,763

-65,909

-66,667

-20,561

-35,461

-42,281

-43,157

-36,538

-23,317

-16,119

-10,819

0

0

0

Accretion of Series D redeemable convertible preferred stock dividends

-

-

0

0

-

66

1,244

2,298

3,195

4,017

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net loss attributable to common stockholders

-

-

-82,297

-86,930

-

-125,778

-131,468

-188,122

-172,287

-109,322

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net loss per share, basic and diluted (in dollars per share)

-0.40

-0.05

-0.30

-0.97

-0.67

0.70

-0.71

-1.11

-4.62

-10.55

-38.31

-3.78

-3.14

-0.09

-0.17

-0.19

-0.44

-16.46

-1.26

-0.69

-0.50

9.08

-7.31

-4.13

-3.00

Weighted-average shares used to compute net loss per share, basic and diluted (in shares)

48,195

51,058

46,239

36,732

26,883

25,980

25,778

20,868

14,974

1,959

1,959

1,959

1,959

264,829

13,816

13,800

13,757

-31,919

13,702

13,676

13,671

6,431

552

552

533